CD30 EXPRESSION IN PRIMARY ORAL/OROPHARYNGEAL DIFFUSE LARGE B-CELL LYMPHOMA, NOS

• Published in: Oral surgery, oral medicine, oral pathology and oral radiology oral medicine, oral pathology and oral radiology, 2022-09, Vol.134 (3), p.e222-e222
• Main Authors: Morais-Perdigão, Ana Luísa, Rodrigues-Fernandes, Carla Isabelly, Vargas, Pablo Agustin, Pontes, Hélder Antônio Rebelo, Martins, Manoela Domingues, De Andrade, Bruno Augusto Benevenuto, Fonseca, Felipe Paiva
• Format: Article
• Language: English
• ISSN: 2212-4403; 2212-4411
• DOI: 10.1016/j.oooo.2022.01.703

To evaluate the expression of CD30 protein in primary oral/oropharyngeal diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). DLBCL, NOS cases diagnosed from 2001 to 2020 were retrieved from pathology files. All cases had their diagnoses confirmed and CD30 expression evaluated by immunohistochemistry. Two cutoff values (>0% and >20%) were used to determine positivity for CD30 in each case. The results were descriptively reported, and statistical analyses were done when necessary. Fifty cases were retrieved and CD30 expression (>0%) was observed in 6 cases. However, 1 case was reclassified as Epstein-Barr virus–positive DLBCL, NOS and 1 case was reclassified as high-grade B-cell lymphoma. Forty-two DLBCL, NOS cases remained, and 4 cases were positive for CD30 (9.5%), with 2 cases demonstrating positivity in >20% of tumor cells. Three cases affected the oral cavity (7.3%) and 1 affected the oropharynx (9.0%). Three cases were classified as nongerminal center B cell type, all with a high proliferative index (>50%), and only 1 patient died during the follow-up period. CD30 expression is uncommon in primary oral/oropharyngeal DLBCL, NOS, which may represent an obstacle for the use of brentuximab vedotin in the majority of these patients.